Pheresis

PROCEDURE13 trials

Sponsors

City of Hope Medical Center, Mayo Clinic, Sumithira Vasu, Fred Hutchinson Cancer Center, Ohio State University Comprehensive Cancer Center

Conditions

Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Undifferentiated LeukemiaBlast Phase Chronic Myeloid Leukemia, BCR-ABL1 PositiveChronic Lymphocytic LeukemiaChronic Myeloid Leukemia, BCR-ABL1 PositiveChronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

Phase 1

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

WithdrawnNCT03100877

City of Hope Medical CenterPlasma Cell Leukemia in Remission, Plasma Cell Myeloma

Start: 2018-01-31End: 2020-05-24Updated: 2017-12-13

Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma

TerminatedNCT03325101

Mayo ClinicStage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 +2

Start: 2017-11-15End: 2020-06-14Updated: 2025-06-12

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

RecruitingNCT03942328

Mayo ClinicStage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8 +3

Start: 2019-09-19End: 2028-02-29Target: 85Updated: 2026-02-24

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

RecruitingNCT05418088

Sumithira VasuRecurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia +15

Start: 2022-06-30End: 2026-07-31Target: 54Updated: 2025-05-16

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

RecruitingNCT05920798

Mayo ClinicFallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma +13

Start: 2023-09-28End: 2027-07-15Target: 40Updated: 2025-06-22

FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia

RecruitingNCT06609928

Fred Hutchinson Cancer CenterRecurrent Childhood Acute Myeloid Leukemia, Refractory Childhood Acute Myeloid Leukemia

Start: 2025-02-24End: 2042-10-01Target: 12Updated: 2026-01-12

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

RecruitingNCT06928662

Fred Hutchinson Cancer CenterAcute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia +11

Start: 2025-09-23End: 2028-11-29Target: 36Updated: 2025-11-06

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

RecruitingNCT06964737

Ohio State University Comprehensive Cancer CenterRecurrent Malignant Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma +3

Start: 2025-05-21End: 2026-12-31Target: 30Updated: 2025-10-29

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

RecruitingNCT07020533

City of Hope Medical CenterAccelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia +9

Start: 2026-05-08End: 2030-02-14Target: 46Updated: 2026-03-27

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

RecruitingNCT07166419

Ohio State University Comprehensive Cancer CenterBlast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia +12

Start: 2026-02-01End: 2026-12-31Target: 24Updated: 2025-12-24

Phase 2

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

RecruitingNCT05672173

City of Hope Medical CenterRecurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome

Start: 2023-06-02End: 2026-09-10Target: 20Updated: 2025-12-15

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

RecruitingNCT06059391

City of Hope Medical CenterAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia +7

Start: 2024-07-12End: 2029-01-01Target: 216Updated: 2026-03-10

Phase 4

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

RecruitingNCT07101445

Emory UniversityMultiple Myeloma

Start: 2025-09-24End: 2027-12-31Target: 94Updated: 2026-02-10

Related Papers

Abstract 7935: Multimodal immunotherapy remodels the tumor microenvironment in hepatocellular carcinoma: Integrative spatial and transcriptomic profiling from a Phase II trial

Cancer Research2026-04-03

Abstract 3741: Radiation-dendritic cell combination therapy drives systemic cellular immune shifts in liver cancer

Cancer Research2026-04-03

Phase I study of FH FOLR1 CAR T for pediatric patients with FOLR1+/CBFA2T3::GLIS2+ relapsed or refractory Acute Myeloid Leukemia

Blood2025-11-03

Preclinical Evaluation of Folate Receptor-α Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma

Cancer Research Communications2025-09-01

Targeting TGFβ docking receptor glycoprotein A repetitions predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma

Neuro-Oncology2025-08-271 citations

Initial Results of a First-in-Human, Phase I Study Point-of-Care Manufacturing of Trispecific CAR-T Cells Targeting CD19/20/22 in B-Cell Malignancies

Blood2024-11-052 citations

Spatial Tissue Analysis of Secondary Sarcoma Following CAR T Cell Therapy for B Cell Lymphoma

Blood2024-11-05

A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)

Blood2022-11-155 citations

689 Preliminary results of a pilot study of intratumoral injection of autologous dendritic cells after high-dose conformal external beam radiotherapy in unreseltable primary liver cancers

Regular and Young Investigator Award Abstracts2022-11-011 citations